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A B S T R A C T
This study aimed to examine the bidirectional relationship between psychotropic medication use and changes in
leisure-time physical activity (LTPA) among a population cohort study. Phase 1 data were collected by mail
surveys in 2000–2002 among 40–60-year-old employees of the City of Helsinki, Finland, and phase 2 follow up
survey was conducted in 2007. Based on self-report, the respondents were classiﬁed as inactive and active
(≥14.75 MET-hours/week) at the phases 1 and 2. Hazard ratios (HR) were calculated for subsequent (2007–10)
psychotropic medication purchasing according to changes in physical activity (phases 1–2). Odds ratios (OR)
for physical inactivity at phase 2 were calculated according to the amount of psychotropic medication between
phases 1–2. Overall, 5361 respondents were included (mean age 50 years, 80% women). Compared with the
persistently active, the persistently inactive, those decreasing and adopting LTPA had an increased risk for
psychotropic medication. Only the persistently inactive remained at increased risk for psychotropic medication
use, following the adjustment for prior psychotropic medication use. Compared with those having no
medication, the risk for physical inactivity increased as the psychotropic medication increased. Our data
suggest that physical activity has an important role in maintaining wellbeing and reducing psychotropic
medication usage.
1. Introduction
Physical activity has a range of beneﬁts for health and well-being
(Penedo and Dahn, 2005). Conversely, physical inactivity is attributed
as the fourth leading cause of preventable mortality in the world,
largely due to the increased cardiovascular risk proﬁle (Kohl et al.,
2012). Recently, interest has begun regarding the beneﬁcial inﬂuence
of physical activity on promoting good mental health. For instance,
Mammen and Faulkner (2013) found in a systematic review that
physical activity has a protective eﬀect from future depression. The
evidence base for physical activity and good mental health is increas-
ing, with more and more interest developing to see if physical activity
can prevent the onset of poor mental health outcomes. Moreover, in
those with a pre-existing mental illness, exercise (a structured form of
physical activity) has been demonstrated to improve depressive
symptoms (Bridle et al., 2012; Rosenbaum et al., 2014; Carter et al.,
2015; Schuch et al., 2016) and symptoms of schizophrenia including
cognition (Firth et al., 2015, 2016).
While promoting physical activity and exercise are gaining cred-
ibility, pharmacotherapy remains the cornerstone for the multidisci-
plinary treatment of many people with mental health problems. In the
past decade, the use of psychotropic medication has substantially
increased, partly owing to the regulatory broadening of the indications
for several psychotropic medications (Mojtabai and Olfson, 2010; Wu
et al., 2013). Psychotropic medication is typically eﬀective in alleviating
mental health symptoms but also often has various side eﬀects. In
particular antipsychotics and to a lesser extent antidepressants and
mood stabilizers, are associated with an increased risk for several
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chronic physical diseases, obesity, diabetes and cardio-metabolic
diseases (Correll et al., 2015; Vancampfort et al., 2015a, 2015b).
Higher dosages, polypharmacy, and treatment of vulnerable (e.g., old
or young) individuals are associated with greater absolute (elderly) and
relative (youth) risk. To what degree medication-speciﬁc and patient-
speciﬁc risk factors interact, and how adverse outcomes can be
minimized, allowing patients to derive maximum beneﬁts from these
psychotropic medications, requires adequate clinical attention and
further research (De Hert et al., 2011). For example, since it is known
that physical inactivity is an important risk factor for a wide range of
chronic diseases and premature mortality (Kodama et al., 2009; Lahti
et al., 2014), research is required to investigate whether psychotropic
medication is a risk factor for lower physical activity and therefore
future increased risk of cardiovascular disease outcomes. Surprisingly,
no longitudinal, population cohort studies have considered whether
higher levels of physical activity are associated with lower psychotropic
medication use and if psychotropic medication is associated with less
physical activity in the future. Understanding this relationship may
have potential importance for mental health promotion, in addition to
help identify if those in receipt of psychotropic medication are at risk of
declining physical activity and therefore more at risk of cardio-
metabolic diseases.
Given the aforementioned, we set out to explore the bidirectional
relationship between (a) changes in leisure-time physical activity and
subsequent psychotropic medication use, and (b) psychotropic medica-
tion use and subsequent physical inactivity using data from the
Helsinki Health Study (Lahelma et al., 2013).
2. Methods
2.1. Study population
The data from the current study were collected as part of the
Helsinki Health Study. The Helsinki Health Study cohort was set up to
enable longitudinal studies on the social and work related determinants
of health and well-being, making use of self-reported as well as
objective register data. The target population is the staﬀ of the City
of Helsinki, Finland (Lahelma et al., 2013). Follow-up survey data were
collected from midlife employees of the City of Helsinki, Finland, at two
time points: phase 1 (2000–2002) and phase 2 (2007) (Lahelma et al.,
2013). Phase 1 data were collected by postal questionnaire surveys in
2000, 2001 and 2002. Questionnaires were mailed to all employees of
the City of Helsinki who reached the age of 40, 45, 50, 55 and 60 during
each survey year. The study has been approved by the ethics commit-
tees of the Department of Public Health, University of Helsinki and the
health authorities of the City of Helsinki.
2.2. Leisure-time physical activity
The respondents were asked about their average weekly hours of
leisure-time physical activity (commuting included) within the pre-
vious 12 months. Four intensity grades were given: walking, brisk
walking, jogging, and running, or their equivalent activities.
Approximate metabolic equivalents (MET-hours per week) were calcu-
lated for the volume of weekly leisure time physical activity. MET-
hours per week were calculated by multiplying the time spent
physically active by the estimated MET value of each four intensity
grades (Kujala et al., 1998) and adding the four values together
(Ainsworth et al., 2000). Respondents were classiﬁed as inactive
according to the lowest tertile (under 14.75 MET-hours/week) or
active when above this threshold (at least 14.75 MET-hours/week
(Lahti et al., 2014). These two groups at the phases 1–2 yielded four
groups describing persistency and changes over time in leisure-time
physical activity.
2.3. Psychotropic medication
The purchases of prescribed psychotropic medication were classi-
ﬁed according to the Anatomical Therapeutic Chemical (ATC) classiﬁ-
cation system (WHO Collaborating Centre for Drug Statistics
Methodology, 2009). Any psychotropic medication included ATC codes
N05 and N06 except medication for dementia N06D. The follow-up
started on the day of returning the phase 1 questionnaire and
continued for the entire year 2010. For examining the two separate
research questions, psychotropic medication purchases were calculated
separately for the period between phases 1–2 and the period after
phase 2. For the ﬁrst period (phases 1–2), the amount of psychotropic
medication was calculated as deﬁned daily doses (DDD's) i.e. the
assumed medication dose per day used for its main indication. The
DDD's were classiﬁed into four groups according to tertiles of medica-
tion use: 1. No medication, 2. Low < 100 DDD's, 3. Medium=100–700
DDD's and 4. High > 700 DDD's. For the second period, the time to the
ﬁrst purchase was examined.
2.4. Covariates
Covariates included age, gender, socioeconomic position (SEP),
smoking, binge drinking, body mass index (BMI) and physical func-
tioning. The information on socioeconomic position (SEP) was taken
from the phase 1 survey including four occupational social classes:
managers (managerial and administrative work) and professionals (e.g.
teachers and doctors), semi-professionals (e.g. nurses and foremen),
routine non-manual (e.g. child minders and assistant maids) and
manual workers (e.g. transport and cleaning work) (Lahelma et al.,
2013). Smoking status change between phases 1 and 2 was classiﬁed
into four groups: 1. non-smokers, 2. became non-smokers, 3. became
smokers and 4. smokers. Similar procedure was applied for binge
drinking (≥6 portions of alcohol more than once a month) (Paljärvi
et al., 2009), being overweight (BMI ≥25 kg/m2) (Svärd et al., 2016)
and lowered physical functioning (under the maximum score of 100)
measured by the physical functioning subscale of the Short-Form (SF-
36) health questionnaire (Ware, 2000).
2.5. Statistical methods
For estimating the eﬀect of changes in physical activity (phases 1–
2) on the risk of subsequent psychotropic medication use we used Cox
regression analysis to calculate hazard ratios (HR) and their 95%
conﬁdence intervals (95% CI) for ﬁrst psychotropic medication pur-
chase during the follow-up period 2007–2010. The persistently active
group was used as the reference group. In model 1 age and gender were
adjusted for. In model 2 covariates in model 1 and prior psychotropic
medication (phases 1–2) were adjusted. In model 3 covariates in model
1 and physical functioning were adjusted. In model 4 covariates in
model 2 and physical functioning, socioeconomic position, smoking,
binge drinking and body mass index were adjusted. The proportional
hazards assumption was conﬁrmed using Schoenfeld residuals
(Schoenfeld, 1982).
For estimating the eﬀect of psychotropic medication use (phases 1–
2) on the risk for physical inactivity (phase 2) we calculated odds ratios
(OR) and their 95% CI's for physical inactivity according to the amount
of psychotropic medication purchases. Psychotropic medication pur-
chase groups were compared to those without medication purchases. In
model 1 age and gender were adjusted for. In model 2 covariates in
model 1 and physical functioning were adjusted for. In model 3
covariates in model 1 and physical inactivity (phase 1) were adjusted.
In model 4 covariates in model 1 and socioeconomic position, smoking,
binge drinking and body mass index were adjusted for. SPSS 23
statistical package was used.
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3. Results
3.1. Study population
The target population consisted of 13346 employees. The response
rates were 67% (n=8960) for phase 1 survey and 83% (n=7332) for the
phase 2 survey. The questionnaire survey data were linked with the
national register on prescribed, reimbursed psychotropic medication
purchases obtained from the Social Insurance Institution of Finland
(74% of the phase 1 respondents gave informed written consent for the
linkages). According to our non-response analyses, there were only
minor diﬀerences between the survey respondents and non-respon-
dents, although younger men and manual workers were slightly
underrepresented among the respondents (Lahelma et al., 2013;
Laaksonen et al., 2008). Not consenting to the data linkage showed
even smaller diﬀerences than the survey non-response (Lahelma et al.,
2013; Laaksonen et al., 2008). There were missing data in some of the
study variables (n=214). The analyses included 5361 (80% women)
respondents.
Among the 5361 participants (mean age 50 years) approximately
16% were persistently inactive from phase 1 to phase 2 and 53% were
persistently active (Table 1). Approximately 16% moved from inactive
Table 1
Description of study variables by leisure time physical activity change groups.
Leisure-time physical activity Phase 1 Inactive Active Inactive Active
Phase 2 Inactive Inactive Active Active All
N (%) 911 (17) 728 (14) 864 (16) 2858 (53) 5361
Women (%) 80 81 82 79 80
Age (mean) 51 49 50 49 50
Socioeconomic position (%)
Manual workers 17 16 11 12 13
Routine non-manuals 35 38 33 33 34
Semi-professionals 18 19 21 21 20
Managers/professionals 31 27 35 34 33
Smoking (%)
Smokers 21 21 15 13 16
Became smokers 2 1 1 2 2
Became non-smokers 7 7 7 5 6
Non-smokers 69 71 77 81 77
Binge drinking (%)
Binge drinkera 19 19 15 14 16
Became binge drinker 6 9 6 7 7
Became non-binge drinker 7 6 5 6 6
Non-binge drinker 68 67 74 73 71
Body mass index (%)
Overweightb 61 51 47 36 44
Became overweight 9 13 10 10 10
Became normal weight 5 3 5 4 4
Normal weight 26 33 39 50 42
Psychotropic medication Phases 1–2 (%)
High ( > 700 DDD)c 13 11 8 7 9
Medium (100–700 DDD) 11 11 11 8 9
Low ( < 100 DDD) 11 8 10 10 10
No medication 66 67 72 75 72
Physical functioning (%)
Sub-optimal functioning 72 62 56 42 52
Became sub-optimal 11 15 16 17 16
Became optimal 6 6 11 10 9
Optimal functioning 11 15 17 31 23
a ≥6 portions of alcohol more than once a month.
b ≥25 kg/m2.
c Deﬁned Daily Dose.
Table 2
Hazard ratios (95% CI) and proportions (%) for any psychotropic medication purchase
after phase 2 by leisure-time physical activity change groups.
Leisure time physical
activity
Psychotropic
medication
Model 1 Model 2 Model 3 Model 4
Phase 1 Phase 2 %
Inactive Inactive 32 1.61
(1.40–
1.85)
1.37
(1.19–
1.58)
1.39
(1.20–
1.60)
1.37
(1.18–
1.58)
Active Inactive 29 1.39
(1.19–
1.62)
1.14
(0.98–
1.34)
1.24
(1.06–
1.45)
1.15
(0.98–
1.35)
Inactive Active 25 1.19
(1.02–
1.39)
1.13
(0.97–
1.32)
1.11
(0.95–
1.30)
1.13
(0.97–
1.32)
Active Active 21 1.00 1.00 1.00 1.00
Model 1 adjusted for age and gender.
Model 2 Model 1+ psychotropic medication phases 1–2.
Model 3 Model 1+ physical functioning.
Model 4 Model 2+ physical functioning, socioeconomic position, binge drinking,
smoking, BMI.
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to active and 14% from active to inactive. In comparison, we calculated
the proportions among those who did not consent to the register
linkage (n=1533) which found only minor non-signiﬁcant diﬀerences;
persistent inactivity showed slightly more common (20%) and persis-
tent activity less common (50%) than among the consenters. Among
the study participants, those persistently active and those who became
active tended to come less often from lower SEP groups (Table 1). In
addition, they tended to be less often smokers and binge drinkers.
There was also a tendency showing that those persistently active had
less often overweight. Approximately 28% of the respondents had
psychotropic medication between phases 1–2 and the persistently
active tended to have less often high psychotropic medication use
and more often no medication.
3.2. The eﬀect of changes in physical activity on the risk of
psychotropic medication use
During the 2.3 years follow-up after phase 2, 25% of the respon-
dents received psychotropic medication, ranging from 21% among the
persistently active to 32% among the persistently inactive (Table 2).
Testing for interactions showed that the associations were similar for
women and men (p=0.9). Compared with the persistently active, those
persistently inactive (HR=1.61, 95%CI=1.40–1.85), those decreasing
(HR=1.39, 95%CI=1.19–1.62) and those adopting (HR=1.19, 95%
CI=1.02–1.39) physical activity had increased risk for the initiation of
psychotropic medication in the age and gender adjusted model. Only
the persistently inactive (HR=1.37, 95%CI=1.19–1.58) remained at
increased risk for psychotropic medication use, when adjustment was
made for prior psychotropic medication (Model 2). Similarly, adjusting
for physical functioning attenuated the associations, whereas, additive
adjustment for confounders had no eﬀect.
3.3. The eﬀect of psychotropic medication use on the risk for physical
inactivity
Compared with those having no medication, the prevalence of
physical inactivity at phase 2 increased in a dose-response manner as
the amount of psychotropic medication use increased, ranging from
28% among those with no medication to 41% among those in the
highest third ( > 700 DDD's) of medication use (Table 3). Testing for
interactions showed that the associations were similar for women and
men (p=0.2). In the age and gender adjusted model, compared to those
without medication, those in the highest third of psychotropic medica-
tion purchases, had the highest risk for subsequent inactivity
(OR=1.72, 95%CI=1.41–2.10). Those in the middle (OR=1.42, 95%
CI=1.16–1.72) and those in the lowest third (OR=1.24, 95%CI=1.02–
1.50) had also signiﬁcantly increased risk for inactivity. Adjusting for
physical functioning attenuated the associations and only the highest
medication group remained at increased risk for physical inactivity
(OR=1.45, 95%CI=1.18–1.77). Whereas adjusting for inactivity at
phase 1 and other confounders had only slight attenuating eﬀects.
4. Discussion
To the best of our knowledge the current study is the ﬁrst to explore
the longitudinal bidirectional relation between psychotropic medica-
tion use and changes in leisure-time physical activity. Our data show
that persistently inactive people had an increased risk for the initiation
of psychotropic medication compared with persistently active persons.
Conversely, compared to those not in receipt of medication, the risk for
subsequent physical inactivity increased in a dose-response manner as
the amount of psychotropic medication increased. In summary, our
results suggest a longitudinal inverse relationship between physical
activity and mental health (expressed as psychotropic medication use).
Therefore, the potential for physical activity to maintain and promote
positive mental health and apparently reduce the need for psychotropic
medication is important.
A number of studies have previously reported that decreases in
physical activity levels over time increases the risk of developing
depression (Camacho et al., 1991; Carroll et al., 2010), and vice versa
(Gudmundsson et al., 2015). Moreover increasing levels of physical
activity can reduce the risk of subsequent depression (Ball et al., 2009;
Brown et al., 2005), and even maintaining some physical activity is
associated with a lower risk of depression compared to those who
remain totally inactive (Wise et al., 2006). Given the importance of
maintaining good mental health and viewing psychotropic medication
as a last resort to treat a mental disorders, our data suggest that
maintaining physical activity levels may have a protective eﬀect from
subsequent psychotropic medication use. This is encouraging, particu-
larly given the multiple side eﬀects associated with psychotropic
medication (Correll et al., 2015). Overall, the ﬁndings from our study
suggest that increasing and maintaining physical activity over time
should be encouraged in order to reduce the risk of developing poor
mental health and being prescribed psychotropic medication. An
alternative explanation of our data might be that the physical (in)
activity is actually a proxy for mental health symptoms. For instance, it
could be hypothesised that higher level of mental health symptoms
require psychotropic medication and may therefore be related to lower
levels of inactivity. Clearly, future longitudinal research is required to
disentangle the relationships we observed and should attempt to
ascertain the impact of mental health symptom severity.
Diﬀerent mechanisms for the protective role of physical activity on
psychotropic medication use can be hypothesised. On a neurobiological
front, a number of acute changes occur during and following bouts of
physical activity, and several long-term adaptations are related to
regular physical activity. For instance, physical activity has been found
to normalize reduced levels of brain-derived neurotrophic factor and
therefore has neuro-protective or even neurotrophic eﬀects (Szuhany
et al., 2015). Animal studies have found physical activity-induced
changes in the levels of diﬀerent neurotransmitters such as dopamine
(Clark et al., 2015), serotonin (Otsuka et al., 2016), glutamate (Real
et al., 2010), and acetylcholine (Uchida et al., 2006), which relate to
mood and beneﬁcial eﬀects on stress reactivity (e.g., the hypothalamus-
pituitary-adrenal axis). Potential psychosocial mechanisms include
Table 3
Odds ratios (95% CI) and proportions (%) for physical inactivity (phase 2) by any psychotropic medication (phases 1–2).
Psychotropic medication Inactive phase 2 Model 1 Model 2 Model 3 Model 4
Phases 1–2 (%)
High > 700 DDD 41 1.72 (1.41–2.10) 1.45 (1.18–1.77) 1.65 (1.33–2.03) 1.53 (1.25–1.87)
Medium 100–700 DDD 36 1.42 (1.16–1.72) 1.20 (0.98–1.46) 1.32 (1.07–1.63) 1.33 (1.09–1.63)
Low < 100 DDD 33 1.24 (1.02–1.50) 1.09 (0.90–1.33) 1.23 (1.00–1.51) 1.23 (1.01–1.50)
No 28 1.00 1.00 1.00 1.00
Model 1 adjusted for age and gender.
Model 2 Model 1+ physical functioning.
Model 3 Model 1+ physical inactivity at phase 1.
Model 4 Model 1+ socioeconomic position, binge drinking, smoking, BMI.
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social reinforcement, experience of mastery in dealing with mental
health problems, shift of external to more internal locus of control,
improved coping strategies, or physical activity as distraction (Daley,
2002; Fox, 1999).
Conversely, our data suggest that psychotropic medication use
(particularly among those with the highest DDD), is associated with
future inactivity. Given the fact that psychotropic medication increases
the risk of weight-gain and chronic physical diseases (Correll et al.,
2015) and that physical activity may have a protective role in
preventing such unwanted consequences (Rosenbaum et al., 2014),
there is a need to develop appropriate future interventions to increase
physical activity in this population. Previous research in people with
recognised mental illnesses, such as depression (Stubbs et al., 2016)
and schizophrenia (Vancampfort et al., 2015a, 2015b), have demon-
strated that lower drop outs from physical activity are associated with
supervision by qualiﬁed professional groups (e.g. physical therapists
and/or exercise physiologists). Therefore, in those with particularly
high psychotropic medication doses, interventions delivered by specia-
lists may be required. Given the large numbers of people in receipt of
psychotropic medication and the increased associated morbidity,
investment in resources to increase physical activity in daily life for
people receiving psychotropic medication may oﬀer excellent value,
both economically and from a mental and physical health perspective.
Whilst our results are novel and of interest, it is important that
future prospective population cohort studies are conducted to conﬁrm
our ﬁndings. Future prospective cohort studies should if possible
consider people across a spectrum of socioeconomic positions, both
genders and attempt to disentangle the bidirectional relationship
between diﬀerent psychotropic agents. The latter will be particularly
helpful to clinicians and those who prescribe medication. Moreover,
future research should attempt to consider the impact of sedentary
behaviour and capture this together with physical activity using
appropriate objective methods such as accelerometers. Finally, future
research should consider if physical activity prescription can prevent
the need for psychotropic medication within a large pragmatic rando-
mised control trial. Only under such circumstances will it be possible to
address the question of causality in the associations we observed.
4.1. Strength and limitations
The current study has a number of strengths. We utilised a large
cohort including both women and men exploring bidirectional associa-
tions between changes in leisure-time physical activity participation
and psychotropic medication use. Next to this, we were able to control
for a wide range of important covariates including age, gender, socio-
economic position, smoking, binge drinking, BMI and physical func-
tioning. However, unmeasured and residual confounding is possible.
The present ﬁndings need, however, be interpreted with caution as well
because of some limitations of our data. Firstly, the participants were
middle-aged public sector employees and 80% of them were women
corresponding to the gender distribution of the target population and
the municipal sector in Finland. Whilst the results are overrepresented
by females, the associations we observed in our study were similar
among women and men. Hence our data are not representative for the
entire population, in particular for the most vulnerable groups for
instance those being unemployed. Another limitation was the reliance
on self-reported recall physical activity that lack validation, however,
no single physical activity questionnaire has proven superior (van
Poppel et al., 2010). Thirdly, non-response and attrition may be a
problem in longitudinal cohort studies. In our study, the phase 1
response rate (67%) was acceptable and good for the phase 2 (83%). In
addition, there was further attrition due to consenting to the register
linkage. According to our non-response analyses e.g. the non-respon-
dents were somewhat younger and from lower occupational classes and
had slightly more long sickness absences than the responders, however,
the diﬀerences were small and thus the results are unlikely to be
markedly biased (Lahelma et al., 2013; Laaksonen et al., 2008). In
addition, we showed that those consenting and not consenting to the
register linkage had similar patterns of leisure-time physical activity
between phases 1–2, although physical inactivity was somewhat more
common among the non-consenters. Due to attrition and the fact that
all participants were initially employed the participants are a selected
group i.e. healthier and physically more active than the general
population and thus the results are probably conservative showing
weaker associations than for general population (Li and Sung, 1999).
The medication data came from national health register. They are
likely to be accurate since the information is originally collected for
administrative purposes and used as the basis for monetary reimburse-
ments. However, the purchases of prescribed psychotropic medication
may not be considered as a direct measure of mental health problems.
Whilst psychotropic medication is primarily utilised to treat common
mental disorders, the use of certain classiﬁcations, such as antidepres-
sants, is increasing for other conditions such as pain and sleep
problems. In addition, there is comorbidity between common mental
disorders such as anxiety and depression (Scott et al., 2007) and
antidepressants are also prescribed for anxiety disorders (Sihvo et al.,
2006) and we do not know the speciﬁc mental disorders that these
medications were prescribed for. Our previous analyses have, however,
shown similar associations between leisure-time physical activity and
use of antidepressants and sedatives (Lahti et al., 2013). Thus we chose
to use any psychotropic medication in our analyses examining the
bidirectional associations in a longitudinal setting.
5. Conclusions
We examined bidirectional relationship between physical activity
and psychotropic medication and found that physical activity is
associated with a reduced need for psychotropic medication after
adjusting for pertinent confounders. Moreover, psychotropic medica-
tion use, particularly in high doses, is associated with less physical
activity. Given these ﬁndings, our data suggest that physical activity has
an important role in maintaining wellbeing and reducing the need for
psychotropic medication.
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